ATE544847T1 - Verwendung von dendritischen zellen, die interleukin 12 (il-12) exprimieren - Google Patents

Verwendung von dendritischen zellen, die interleukin 12 (il-12) exprimieren

Info

Publication number
ATE544847T1
ATE544847T1 AT03794972T AT03794972T ATE544847T1 AT E544847 T1 ATE544847 T1 AT E544847T1 AT 03794972 T AT03794972 T AT 03794972T AT 03794972 T AT03794972 T AT 03794972T AT E544847 T1 ATE544847 T1 AT E544847T1
Authority
AT
Austria
Prior art keywords
cells expressing
dendritic cells
expressing interleukin
interleukin
dendritic
Prior art date
Application number
AT03794972T
Other languages
English (en)
Inventor
Thomas Felzmann
Original Assignee
Forsch Krebskranke Kinder
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forsch Krebskranke Kinder filed Critical Forsch Krebskranke Kinder
Application granted granted Critical
Publication of ATE544847T1 publication Critical patent/ATE544847T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4634—Antigenic peptides; polypeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/53—Liver
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/56—Kidney
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C12N2501/052—Lipopolysaccharides [LPS]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT03794972T 2002-09-13 2003-08-29 Verwendung von dendritischen zellen, die interleukin 12 (il-12) exprimieren ATE544847T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0137502A AT412145B (de) 2002-09-13 2002-09-13 Verfahren zur herstellung eines zellulären immuntherapeutikums auf basis von il-12-freisetzenden dendritischen zellen
PCT/EP2003/009591 WO2004024900A1 (en) 2002-09-13 2003-08-29 USE OF DENDRITIC CELLS (DCs) EXPRESSING INTERLEUKIN 12 (IL-12)

Publications (1)

Publication Number Publication Date
ATE544847T1 true ATE544847T1 (de) 2012-02-15

Family

ID=31892564

Family Applications (2)

Application Number Title Priority Date Filing Date
AT0137502A AT412145B (de) 2002-09-13 2002-09-13 Verfahren zur herstellung eines zellulären immuntherapeutikums auf basis von il-12-freisetzenden dendritischen zellen
AT03794972T ATE544847T1 (de) 2002-09-13 2003-08-29 Verwendung von dendritischen zellen, die interleukin 12 (il-12) exprimieren

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT0137502A AT412145B (de) 2002-09-13 2002-09-13 Verfahren zur herstellung eines zellulären immuntherapeutikums auf basis von il-12-freisetzenden dendritischen zellen

Country Status (12)

Country Link
US (1) US7867488B2 (de)
EP (1) EP1537203B1 (de)
JP (1) JP2005538167A (de)
AT (2) AT412145B (de)
AU (1) AU2003260473B2 (de)
CA (1) CA2494216C (de)
CY (1) CY1112740T1 (de)
DK (1) DK1537203T3 (de)
ES (1) ES2381870T3 (de)
PT (1) PT1537203E (de)
SI (1) SI1537203T1 (de)
WO (1) WO2004024900A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1757680B1 (de) * 2004-05-11 2009-09-16 Shukokai Incorporated Methoden zur Kultivierung von Antigen presentierenden Immunzellen
AU2013206016B2 (en) * 2005-12-08 2016-08-11 Northwest Biotherapeutics, Inc. Compositions and methods for inducing the activation of immature monocytic dendritic cells
KR20150082688A (ko) * 2005-12-08 2015-07-15 노쓰웨스트 바이오써라퓨틱스, 인크. 미성숙 단핵구성 수지상 세포의 활성화를 유도하기 위한 조성물 및 방법
EP2072617A1 (de) * 2007-12-12 2009-06-24 Trimed Biotech GmbH Verfahren zur Herstellung dendritischer Zellen
JP2013522309A (ja) * 2010-03-15 2013-06-13 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 活性化した成熟樹状細胞を調製し保存するシステムおよび方法
SG11201510552WA (en) * 2012-06-27 2016-01-28 Hasumi Internat Res Foundation Therapy and method for intratumorally introducing cytotoxic t lymphocyte and/or nkt cell with anti-tnf and/or anti-il-10
WO2014149871A1 (en) 2013-03-14 2014-09-25 Icahn School Of Medicine At Mount Sinai Autologous tumor lysate-loaded dendritic cell vaccine for treatment of liver cancer
EP2787005A1 (de) 2013-04-02 2014-10-08 Activartis Biotech GmbH Gezielte Krebs-Immuntherapie

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6479254B2 (en) * 1996-03-22 2002-11-12 Human Genome Sciences, Inc. Apoptosis inducing molecule II
FR2796961B1 (fr) * 1999-07-29 2003-05-02 Chu Montpellier Procede d'obtention de cellules dentritiques, les cellules dentritiques ainsi obtenues et leurs utilisations a des fins cliniques
AU2575201A (en) * 1999-12-03 2001-06-12 University Of Massachusetts Use of hsp27 as an anti-inflammatory agent
AU2000227285A1 (en) * 2000-01-14 2001-07-24 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Methods of regulating il-12 production by administering ccr5 agonists and antagonists
WO2002034887A2 (en) * 2000-10-24 2002-05-02 Schering Corporation Maturation of dendritic cells
WO2003022215A2 (en) * 2001-09-06 2003-03-20 Northwest Biotherapeutics, Inc. Compositions and methods for priming monocytic dendritic cells and t cells for th-1 response

Also Published As

Publication number Publication date
CY1112740T1 (el) 2016-02-10
AU2003260473A1 (en) 2004-04-30
CA2494216A1 (en) 2004-03-25
ATA13752002A (de) 2004-03-15
AU2003260473B2 (en) 2008-08-07
WO2004024900A1 (en) 2004-03-25
ES2381870T3 (es) 2012-06-01
EP1537203A1 (de) 2005-06-08
AT412145B (de) 2004-10-25
US7867488B2 (en) 2011-01-11
DK1537203T3 (da) 2012-05-14
SI1537203T1 (sl) 2012-06-29
JP2005538167A (ja) 2005-12-15
CA2494216C (en) 2013-07-09
PT1537203E (pt) 2012-05-21
EP1537203B1 (de) 2012-02-08
US20060177420A1 (en) 2006-08-10

Similar Documents

Publication Publication Date Title
CY1117029T1 (el) Συνεργιστικοι μυκητοκτονοι συνδυασμοι δραστικων ουσιων
ITTO20040797A1 (it) Composizione per il rimpiazzo di carboidrati ed elettroliti.
DE60336396D1 (de) Zellenbaugruppe des fest-hochpolymertyps
CY2014041I2 (el) 2,3-διυδρο-6-νιτροϊμιδαζο 2,1 -b-οξαζολια
FR2836914B1 (fr) Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
AU2003237788A8 (en) Electrode constructs, and related cells and methods
ATE267246T1 (de) Künstliche chromosomen, die die genetische information für die bildung von rekombinantem rna-virus enthalten
NO20052975D0 (no) Nye 2',5'-oligoadenylsyreanaloger.
DE60315019D1 (de) Entfernbarer hydraulikschlauchträger
ATE544847T1 (de) Verwendung von dendritischen zellen, die interleukin 12 (il-12) exprimieren
DE50300979D1 (de) Verwendung von Makromonomeren für die Herstellung von Acrylathaftklebemassen
AU2003220249A1 (en) Improved nucleic acid amplification
AU2003279509A8 (en) Targeted double stranded rna mediated cell killing
AU2003287521A1 (en) Pluripotent cells from monocytes, and methods of making and using pluripotent cells
IS7609A (is) 2,5-tvíútskipt 3-merkaptópentansýra
AU2003284127A8 (en) Nucleic acid supported protein complementation
ATE533779T1 (de) Isoliertes photoprotein mtclytin, sowie dessen verwendung
ATE370964T1 (de) Isoliertes fluoreszierendes protein aus clytia gregaria cgfp, sowie dessen verwendung
ITRM20010056A0 (it) Apparecchiatura per la fermentazione di sostanze, in particolare per vinificazione.
NO20044120L (no) Elektrolytisk diafragmacelle
DE50302820D1 (de) Kraftaufnehmer
WO2005082088A3 (en) Functional genomics and gene trapping in haploid or hypodiploid cells
DE10390251D2 (de) Trojanische Inhibitoren, Verfahren zu ihrer Herstellung und ihre Verwendung
AU2003235132A1 (en) Honey, novel honey composition and process for producing the same
AU2003219570A1 (en) Novel dendritic cell-specific polynucleotides and microarray comprising the same